About the Company
Expanding immune system stimulation to revolutionize vaccines… That is Inovio’s (NYSE MKT: INO) quest. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease. At Inovio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.
PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study...
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today reported financial results for the quarter ended March 31, 2017. Total revenue was $10.4 million for the three months ended March 31, 2017, compared to...
Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate...
Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
PLYMOUTH MEETING, Pa. and TARRYTOWN, N.Y., May 08, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) and Regeneron Pharmaceuticals, Inc. (REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial. The study will be conducted by...